Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER

(PFE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Pfizer : Sees Positive Top-Line Results in Abrocitinib Study

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/15/2019 | 07:16am EDT

By Chris Wack

Pfizer Inc. (PFE) said Wednesday that it saw positive top-line results from a Phase 3 pivotal study for its investigational oral Janus kinase 1 inhibitor, abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis.

The pharmaceutical company said in a release that top-line results showed that by week 12, the percentage of patients achieving each co-primary efficacy endpoint and each key secondary endpoint with either dose of abrocitinib was statistically significantly higher than placebo.

Pfizer said the results demonstrate response to treatment for a statistically significant number of patients during the first two to four weeks following the first dose.

The company said that safety results showed that both doses of abrocitinib were well-tolerated and there were no unexpected safety events. The discontinuation rates due to an adverse event were low in each treatment arm compared to placebo.

Write to Chris Wack at chris.wack@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
09:28aPFIZER : Verily partners with pharma giants, promising to transform clinical res..
AQ
06:56aSANOFI : Verily signs up four big pharmas to its clinical trials platform
AQ
06:37aPFIZER : Alphabet's Verily teams with pharma companies to improve clinical trial..
AQ
04:37aPFIZER : Googles life sciences sister plugs Big Pharma into the mainstream in a ..
AQ
04:37aPFIZER : Novartis, Otsuka, Pfizer, Sanofi commit to new trials on Verily's digit..
AQ
05/22PFIZER : Description Statement of Ownership
PU
05/20PFIZER : Confirms Initiation of EU Review of Tofacitnib with Interim Recommendat..
PU
05/18PFIZER : Eczema Candidate Meets All Goals In Phase III Study
AQ
05/17PFIZER : confirms initiation of EU review of Tofacitinib with interim recommenda..
PU
05/17PFIZER : new JAK inhibitor could come after your eczema market
AQ
More news
Financials ($)
Sales 2019 53 201 M
EBIT 2019 19 478 M
Net income 2019 13 317 M
Debt 2019 32 207 M
Yield 2019 3,40%
P/E ratio 2019 17,46
P/E ratio 2020 15,94
EV / Sales 2019 4,99x
EV / Sales 2020 4,89x
Capitalization 233 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 45,1 $
Spread / Average Target 7,4%
EPS Revisions
Managers
NameTitle
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-4.54%233 461
JOHNSON & JOHNSON7.03%368 416
ROCHE HOLDING LTD.9.84%228 186
NOVARTIS13.31%210 460
MERCK AND COMPANY5.98%208 495
ABBVIE-11.50%120 617